Sarepta Therapeutics shares were higher after J.P. Morgan reduced its December 2025 price target to $84 from $169 and maintained its overweight rating.
The stock was up 4% to $39.55 Tuesday and is down about 67% this year.
Sarepta shares closed at $63.66 on May 6 and fell sharply after the company lowered full-year guidance. J.P. Morgan's research note said "Our Overweight rating on SRPT shares is based on valuation disconnect on the potential of Elevidys (even with more conservative estimates)."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 20, 2025 15:01 ET (19:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.